Comments on patents
Lactobacillus rhamnosus strain for reducing body fat accumulation
Title of the invention: Lactobacillus rhamnosus strain for reducing body fat accumulation
Number of the patent: US9855304B2
Date of publication and mention of the grant of the patent: 02.01.2018
Applicant(s): GERVAIS DANONE SA [FR]; BIOPOLIS S L [SPAIN]
Inventor(s): Gianfranco Grompone, Paris (FR); Daniel Ramon Vidal, Valencia (ES); Patricia Martorell Guerola, Valencia (ES); Salvador Genoves Martinez, Valencia (ES); Josefa Ortiz Serrano, Valencia (ES); Silvia Llopis Pla, Valencia (ES); Nuria Gonzalez Martinez, Valencia (ES)
Obesity is an important risk factor for major diseases including hypertension, type II diabetes, cardiovascular diseases, liver diseases and some cancers, it is rapidly becoming a major public health problem. The number of obese people worldwide has more than doubled since 1980. In 2008, more than 1.4 billion adults, 20 and older, were overweight. Of these over 200 million men and nearly 300 million women were obese.
It is generally acknowledged that one of the primary causes of the current frequency of obesity and related metabolic disorders is the combination of reduced physical activity in the daily lives, with the western-style diet, rich in high-fat and high-sucrose foods. However, differences in fat accumulation and body weight among individuals are also correlated with other factors, such as genetic background, health conditions, medical treatments, age, or lack of sleep.
Among these factors, the gut microbiota is the focus of increasing interest. Numerous investigations in recent years have shown that obesity and obesity-related metabolic disorders are associated with changes in the composition of the intestinal microbiota. It has been suggested that manipulation of gut microbiota using prebiotics, probiotics, or synbiotics, may help to reduce obesity and obesity-related metabolic disorders.
Some probiotic strains have been reported to decrease fat accumulation and/or obesity-related metabolic disorders. The effects of these different probiotics are strain-specific, and appear to be mediated by different mechanisms. Thus, a need remains for other probiotic strains that can be used for controlling the development of overweight and obesity and associated metabolic diseases.
The inventors have screened probiotic strains for their ability to modulate lipid metabolism, using Caenorhabditis elegans as an in vivo model and they have found that, among the probiotic strains tested, one strain of Lactobacillus rhamnosus, strain CNCM I-3690, decreased lipid storage to the same extent as orlistat, which is a reversible gastrointestinal lipase inhibitor preventing absorption of dietary fat, and is broadly used as a medication for the management of obesity.
Therefore, the proposed technical solution of the present invention is the use of Lactobacillus rhamnosus strain CNCM I-3690, or of a composition containing said strain, for reducing body fat accumulation in a subject. Lactobacillus rhamnosus strain CNCM I-3690 can be used in the form of whole bacteria which may be living or not. Alternatively, it can be used in the form of a bacterial lysate or in the form of bacterial fractions; the bacterial fractions suitable for this use can be chosen, for example, by testing their properties on lipid storage in C. elegans.
New antibacterial agents against the Gram-negative bacteria Acinetobacter baumannii.
Title of the invention: ARYLHYDRAZIDES CONTAINING A 2-PYRIDONE MOIETY AS SELECTIVE ANTIBACTERIAL AGENTS
Number of the patent: EP 3 174 852 B1
Date of publication and mention of the grant of the patent: 18.07.2018
Proprietor: ABAC THERAPEUTICS, S.L. (Barcelona, Spain)
Inventor(s): Domingo GARGALLO VIOLA, Albert PALOMER BENET
Infections caused by Acinetobacter baumannii (A. baumannii) are increasingly recognized as a serious health threat, especially in healthcare facilities, and are associated with increased morbidity, mortality and duration of hospital stay, as well as with high healthcare costs.
Among the main risk factors for acquiring A. baumannii is the use of artificial devices commonly employed in hospital settings, such as dialysis, mechanical ventilation, sutures or catheters, due to the notorious ability of A. baumannii to survive for extended periods on environmental surfaces.
A. baumannii can cause infections in virtually every organ system of the human body, including pneumonia, surgical site infections, skin and soft tissue infections, urinary tract infections, post-operative meningitis and catheter related infections.
Hospital-acquired pneumonia is the most common life-threatening hospital-acquired infection, and is mainly associated with the use of mechanical ventilation, known as ventilator associated pneumonia (VAP). VAP infections caused by Acinetobacter are between 8% and 35% of total VAP cases.
A. baumannii infections are currently treated with different broad- or semi-broad spectrum antibiotics or combinations, including, for example, the carbapenems imipenem, meropenem and doripenem, which are first choice drugs.
However, treatment of A. baumannii infections is challenging since it has emerged as a highly drug-resistant pathogen, especially carbapenem-resistant, and therefore other alternative broad-spectrum antibacterials are also used in therapy, such as polymyxins (colistin, polymyxin E and polymyxin B), tigecycline, tetracyclines (minocycline and doxycycline) or aminoglycosides (amikacin and tobramycin). None of the currently used treatments are specific for A. baumannii.
There is a need to develop new antibacterial agents that are effective for treating the life-threatening infections caused by Acinetobacter bacteria and that also show a selective antimicrobial pattern to avoid the disadvantages associated to the non-selective broad-spectrum antibiotics currently used in therapy.
The authors have developed a group of arylhydrazides containing a 2-pyridone moiety that show selective antibacterial activity against the Gram-negative bacteria A. baumannii, providing therefore a new therapeutic tool for treating the infections caused by this bacteria in a safer way, while avoiding the damage to the intestinal flora and multiple resistances involved with the treatment with the current broad-spectrum antibacterials.
See also: http://www.abactherapeutics.com/